| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Rheumatology 2003; 42: 326-335
© 2003 British Society for Rheumatology
The cost-effectiveness of infliximab (Remicade®) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study
HDI France, Spéracèdes, France,
1 Stockholm Health Economics Consulting AB, Uppsala, Sweden,
2 Department of Rheumatology, City Hospital, St Albans, UK (for the Early RA Study group) and
3 Department of Rheumatology, Lund University Hospital, Lund, Sweden
Objective. The cost per quality-adjusted life-year (QALY) of infliximab (Remicade®) treatment in rheumatoid arthritis (RA) was estimated on the basis of a clinical trial comparing infliximab plus methotrexate with methotrexate alone in 428 patients with advanced disease [Anti-Tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy (ATTRACT)].
Methods. The effect of infliximab on disease progression and related costs and utilities was estimated using two disease progression models based on epidemiological cohorts followed for up to 15 yr in Sweden and the UK. The clinical trial data were used directly in the model and extrapolated to 10 yr using a cohort from the epidemiological studies matched for gender, age, time since onset of RA and disease severity.
Results. One to two years of treatment with infliximab treatment reduced direct and indirect resource consumption in both countries, thereby partly offsetting the treatment cost. In the base case, including both direct and indirect costs, the cost per QALY gained was SEK 32 000 (€3440) in Sweden and GBP 21 600 (€34 800) for 1 yr of treatment. The respective QALY gains were 0.248 and 0.298. With 2 yr of treatment, the costs per QALY gained were SEK 150 000 (€16 100) and GBP 29 900 (€48 200).
Conclusions. Although 1–2 yr of treatment with infliximab will lead to savings in both direct and indirect costs, these will not offset the drug cost. However, the cost-effectiveness ratios remain within the usual range for treatments to be recommended for use.
KEY WORDS: RA, Cost-effectiveness, Utility, QALY, Cost, Infliximab.
Correspondence to: G. Kobelt, HDI France, 492 Chemin des Laurens, 06530 Spéracèdes, France. E-mail: gisela.kobelt{at}easynet.fr
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. Sany, J.-D. Cohen, C. Combescure, M.-C. Bozonnat, F. Roch-Bras, G. Lafon, and J.-P. Daures Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years Rheumatology, October 1, 2009; 48(10): 1236 - 1241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. BARRA, J. E. POPE, and M. PAYNE Real-World Anti-Tumor Necrosis Factor Treatment in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis: Cost-Effectiveness Based on Number Needed to Treat to Improve Health Assessment Questionnaire J Rheumatol, July 1, 2009; 36(7): 1421 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Vera-Llonch, E. Massarotti, F. Wolfe, N. Shadick, R. Westhovens, O. Sofrygin, R. Maclean, Y. Yuan, and G. Oster Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate Rheumatology, April 1, 2008; 47(4): 535 - 541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Bravo Vergel, N. S. Hawkins, K. Claxton, C. Asseburg, S. Palmer, N. Woolacott, I. N. Bruce, and M. J. Sculpher The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis Rheumatology, November 1, 2007; 46(11): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Kobelt Thoughts on health economics in rheumatoid arthritis Ann Rheum Dis, November 1, 2007; 66(suppl_3): iii35 - iii39. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brennan, N. Bansback, R. Nixon, J. Madan, M. Harrison, K. Watson, and D. Symmons Modelling the cost effectiveness of TNF-{alpha} antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry Rheumatology, August 1, 2007; 46(8): 1345 - 1354. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kuek, B. L Hazleman, and A. J K Ostor Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution Postgrad. Med. J., April 1, 2007; 83(978): 251 - 260. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M Drummond Pharmacoeconomics: friend or foe? Ann Rheum Dis, November 1, 2006; 65(suppl_3): iii44 - iii47. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Pucino Jr., P. T. Harbus, and R. Goldbach-Mansky Use of biologics in rheumatoid arthritis: Where are we going? Am. J. Health Syst. Pharm., September 15, 2006; 63(18 Suppl 4): S19 - S41. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Bansback, R. Ara, N. Barkham, A. Brennan, A. D. Fraser, P. Conway, A. Reynolds, and P. Emery Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis Rheumatology, August 1, 2006; 45(8): 1029 - 1038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Hallert, M. Husberg, and T. Skogh Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project) Rheumatology, March 1, 2006; 45(3): 325 - 331. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Kavanaugh Health economics: implications for novel antirheumatic therapies Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv65 - iv69. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Drummond, M. Barbieri, and J. B. Wong Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference? Med Decis Making, September 1, 2005; 25(5): 520 - 533. [Abstract] [PDF]
|
|
|
|
|
|
G. Kobelt, P. Lindgren, Y. Lindroth, L. Jacobson, and K. Eberhardt Modelling the effect of function and disease activity on costs and quality of life in rheumatoid arthritis Rheumatology, September 1, 2005; 44(9): 1169 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Kobelt, P. Andlin-Sobocki, S. Brophy, L. Jonsson, A. Calin, and J. Braun The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade(R)) Rheumatology, September 1, 2004; 43(9): 1158 - 1166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brennan, N. Bansback, A. Reynolds, and P. Conway Modelling the cost-effectiveness of etanercept in adults with rheumatoid arthritis in the UK Rheumatology, January 1, 2004; 43(1): 62 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. M. Rothschild Infliximab cost-effectiveness/safety? Rheumatology, December 1, 2003; 42(12): 1572 - 1573. [Full Text] [PDF]
|
|
|
|
|
|
P. M. J. Welsing, J. L. Severens, and R. F. J. M. Laan Optimistic assumptions in modelling studies have a substantial influence on the cost-effectiveness result Rheumatology, December 1, 2003; 42(12): 1574 - 1575. [Full Text] [PDF]
|
|
|
|
 |
|
 I. K Nahar, K. Shojania, C. A Marra, A. H Alamgir, and A. H Anis Infliximab Treatment of Rheumatoid Arthritis and Crohn's Disease Ann. Pharmacother., September 1, 2003; 37(9): 1256 - 1265. [Abstract] [Full Text] [PDF]
|
|